A Study of TACE Combined With Atezolizumab Plus Bevacizumab or TACE Alone in Patients With Untreated Heaptocellular Carcionma
A phase 3 trial of Atezolizumab, Bevacizumab in hepatocellular carcinoma, run by Hoffmann-La Roche, active and no longer recruiting.
Overview
A Study of TACE Combined With Atezolizumab Plus Bevacizumab or TACE Alone in Patients With Untreated Heaptocellular Carcionma is a phase 3 interventional study registered as NCT04712643 by Hoffmann-La Roche, with 342 participants enrolled, started 2021-03-12 and due to reach its primary completion in 2029-02-01. Interventions recorded: Atezolizumab, Becavizumab, Transarterial chemoembolization (TACE). Conditions listed: Hepatocellular Carcinoma. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialA Study Evaluating Atezolizumab, With or Without Bevacizumab, in Participants With Unresectable Hepatocellular Carcinoma and Child-pugh B7 and B8 Cirr
Shares Atezolizumab, Roche / Genentech, Bevacizumab, Hepatocellular carcinoma.
- TrialA Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Participants With Untreated Locally Advanced or Metastatic Hepatocell
Shares Atezolizumab, Roche / Genentech, Bevacizumab, Hepatocellular carcinoma.
- TrialA Study of TTI-101 as Monotherapy and in Combination in Participants With Locally Advanced or Metastatic, and Unresectable Hepatocellular Carcinoma
Shares Atezolizumab, Bevacizumab, Hepatocellular carcinoma.
- TrialStudy of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC
Shares Atezolizumab, Bevacizumab, Hepatocellular carcinoma.
- TrialA Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Li
Shares Atezolizumab, Roche / Genentech, Bevacizumab, Hepatocellular carcinoma.
- TrialA Study of Atezolizumab in High PD-L1 Expression, Chemotherapy-Naïve Patients With Stage IV Non-Squamous or Squamous Non-Small Cell Lung Cancer
Shares Atezolizumab, Roche / Genentech.
- TrialPhase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma
Shares Atezolizumab, Bevacizumab, Hepatocellular carcinoma.
- TrialA Study in Participants Previously Enrolled in a Genentech- and/or F. Hoffmann-La Roche Ltd-Sponsored Atezolizumab Study (IMbrella A)
Shares Atezolizumab, Bevacizumab.